Trial Profile
Study on the Safety and Therapeutic Effect of Stereotactic Body Radiotherapy and Anti-PD-1 Antibody in Late Stage or Recurrent Pancreatic Cancer Patients Who Failed in Second-line Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CISPD-2
- 29 Oct 2018 New trial record